Physical activity in adolescents who later developed schizophrenia: A prospective case-control study from the Young-HUNT.

BACKGROUND: Adults suffering from schizophrenia and other psychiatric disorders report low levels of physical activity. In addition, these patients have an increased risk of overweight and poor nutritional habits. Less is known about patterns and levels of physical activity before the onset of disease. AIMS: The purpose of the study was to investigate whether there were specific patterns of physical activity in the premorbid phase of schizophrenia and whether these participants differed from those with bipolar disorder (BD). A group of healthy controls (HC) was also included. METHODS: The study was a prospective, longitudinal, comparative cohort design in which 15 adolescents who later developed schizophrenia and 18 with later BD were compared with HC. Data were analysed using non-parametric statistical tests. RESULTS: Patients with a diagnosis of schizophrenia were less physically active with fewer days per week (p < 0.05) and fewer hours per week (p < 0.05) in the premorbid phase than both BD and HC. They also participated less in team sports than HC (p < 0.05). CONCLUSION: Our results suggest that individuals who develop schizophrenia in their teens may be at risk of establishing a lifestyle harmful to health. From a preventive perspective it is important to gain more knowledge about the connections between health habits and later development of disease.

Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.

There is effective short-term central stimulant (CS) treatment of attention-deficit/hyperactivity disorder (ADHD) symptoms in adult ADHD, and despite this, many patients discontinue the treatment too early. The present study examines the duration of CS treatment in a Norwegian cohort of adult ADHD to identify predictors for long treatment duration (≥ 3 years). The data were based on the medical records of a sample of 117 of all 119 adult ADHD patients diagnosed over a period of 8 years in a specific catchment area and treated with CS. A logistic regression model was applied to identify possible predictors for long treatment duration. The sample was severely impaired in terms of comorbidity, educational achievement, and employment. The median duration of CS treatment was 33.0 months. Use of extended-release formulations of methylphenidate predicted long treatment duration positively (odds ratio, 4.420 [95% CI, 1.875-10.419]), whereas baseline antisocial personality disorder predicted long treatment duration negatively (odds ratio, 0.210 [0.085-0.518]). This study showed that it is possible to treat severely impaired and highly comorbid adult ADHD patients with CS over years. The finding that extended-release formulations of methylphenidate predict long treatment duration supports previous research, and it is important to show this association in naturalistic samples such as in the present study. Comorbid antisocial personality disorder was a negative predictor of long CS treatment duration. Univariate analyses also indicate that comorbid substance use disorder is related to shorter duration of CS treatment.

The Norwegian Translation of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale: Validation and Assessment of QoL in 313 Adults With ADHD.

OBJECTIVE: The aim of the study was to validate the Norwegian version of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life (AAQoL) scale and to explore Quality of Life (QoL) and functional outcomes in adults with ADHD. METHOD: A total of 313 adults with ADHD participated in the study. Data were collected from medical records and self-report questionnaires. Confirmatory factor analysis was performed to assess the model fit of the translated AAQoL. Chi-square statistics and t tests were used to investigate sample characteristics. RESULTS: The analyses showed acceptable model fit between data and the model. Chi square = 863.179 (371 df, p < .0000), root mean square error of approximation (RMSEA) = 0.069 (90% confidence interval [CI]), comparative fit index (CFI) = 0.873, and Tucker-Lewis index (TLI) = 0.821. Cronbach's alpha range for the scales was .761 to .869. The sample was characterized by poor QoL and impairment. CONCLUSION: The translated AAQoL is showing good initial indications of validity with acceptable psychometric properties in the sample. ADHD was associated with impairments in QoL, symptoms, and functional outcomes.

Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients.

INTRODUCTION: Data specific to late-life bipolar disorder (BD) are limited. Current research is sparse and present guidelines are not adapted to this group of patients. OBJECTIVES: We present a literature review on clinical characteristics, comorbidities, and cognitive impairment in patients with late-life BD. This review discusses common comorbidities that affect BD elders and how aging might affect cognition and treatment. METHODS: Eligible studies were identified in MedLine by the Medical Subject Headings terms "bipolar disorder" and "aged". We only included original research reports published in English between 2012 and 2015. RESULTS: From 414 articles extracted, 16 studies were included in the review. Cardiovascular and respiratory conditions, type II diabetes, and endocrinological abnormalities were observed as highly prevalent. BD is associated with a high suicide risk. Bipolar elderly had an increased risk of dementia and performed worse on cognitive screening tests compared to age-matched controls across different levels of cognition. Despite high rates of medical comorbidity among bipolar elderly, a systematic under-recognition and undertreatment of cardiovascular disease have been suggested. CONCLUSION: There was a high burden of physical comorbidities and cognitive impairment in late-life BD. Bipolar elderly might be under-recorded and undertreated in primary medical care, indicating that this group needs an adapted clinical assessment and specific clinical guidelines need to be established.

Optimal management of ADHD in older adults.

BACKGROUND: The manifestation of attention-deficit/hyperactivity disorder (ADHD) among older adults has become an interesting topic of interest due to an increasing number of adults aged 50 years and older (≥50 years) seeking assessment for ADHD. Unfortunately, there is a lack of research on ADHD in older adults, and until recently only a few case reports existed. METHOD: A systematic search was conducted in the databases Medline/PubMed and PsycINFO in order to identify studies regarding ADHD in adults ≥50 years. RESULTS: ADHD persists into older ages in many patients, but the prevalence of patients fulfilling the criteria for the diagnosis at age ≥50 years is still unknown. It is reason to believe that the prevalence is falling gradually with age, and that the ADHD symptom level is significantly lower in the age group 70-80 years than the group 50-60 years. There is a lack of controlled studies of ADHD medication in adults ≥50 years, but this review suggests that many patients aged ≥50 years experience beneficial effects of pharmacological treatment. The problem with side effects and somatic complications may rise to a level that makes pharmacotherapy for ADHD difficult after the age of 65 years. Physical assessment prior to initiation of ADHD medication in adults ≥50 years should include a thorough clinical examination, and medication should be titrated with low doses initially and with a slow increase. In motivated patients, different psychological therapies alone or in addition to pharmacotherapy should be considered. CONCLUSION: It is essential when treating older adult patients with ADHD to provide good support based on knowledge and understanding of how ADHD symptoms have affected health, quality of life, and function through the life span. Individualized therapy for each elderly patient should be recommended to balance risk-benefit ratio when pharmacotherapy is considered to be a possible treatment.

Functional Impairment Mediates the Relationship Between Adult ADHD Inattentiveness and Occupational Outcome.

OBJECTIVE: In spite of an expanding use of health-related quality of life assessment in research and treatment of ADHD, there is still limited knowledge about the role of impaired quality of life in symptomatic outcomes. This study investigates how specific functional domains affect the relationship between ADHD symptoms and occupational outcome. METHOD: A total of 149 referred adults with ADHD participated in the study. We used mediation analyses to test a model with two 36-item short form health survey (SF-36) Mental Component scales, that is, role-emotion function and social function as mediators for the relationship between ADHD inattentiveness and occupational outcome. RESULTS: The relationship between ADHD inattentiveness and occupational outcome was completely mediated by both role-emotion function and social function. CONCLUSION: Role-emotion function and social function may identify specific aspects of functional impairment as potentially important treatment targets for ADHD patients with impaired occupational function. (J. of Att. Dis. 2016; 20(6) 510-518).

ADHD symptoms are differentially related to specific aspects of quality of life.

OBJECTIVE: The objectives of this study were to investigate the relationships between ADHD symptoms and specific domains of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) mental component. METHOD: A sample of 149 adults participated in the study. Data were collected from the participant's medical records and from self-report questionnaires. Multiple regression analyses were applied to identify predictors of the SF-36 mental component outcomes. RESULTS: The sample was highly impaired in terms of low health-related quality of life on all SF-36 mental component scales. The ADHD Self-Report Scale (ASRS) inattentiveness was the strongest predictor of vitality and the only significant predictor of role-emotional outcome. The ASRS hyperactivity/impulsivity was the strongest predictor of social function and the only predictor of mental health outcome. CONCLUSION: Inattentiveness and hyperactivity/impulsivity were differentially related to specific quality-of-life domains. Inattentiveness was significantly predicting vitality and role-emotional outcomes, and hyperactivity/impulsivity predicted social function and mental health outcomes.

Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.

Central stimulant (CS) therapy is a cornerstone in treatment of adult attention-deficit/hyperactivity disorder (ADHD). Substance use disorder (SUD) is a common comorbid disorder of ADHD and might complicate the treatment. Our main objectives were to investigate the prevalence of SUD during CS treatment, and identify variables associated with SUD during the treatment. The collection of data was based on a naturalistic, retrospective approach using the medical records of a cohort of all adult ADHD patients (N = 117) starting treatment with CS in a specific catchment area in the period 1997 to May 2005. A logistic regression model was applied to identify possible predictors of SUD during CS treatment. The study showed no onset of SUD during the CS treatment in the group of patients without comorbid SUD at baseline (mean CS treatment length 41.1 months). In the group of patients with comorbid SUD at baseline, 58.5 % had one or more relapses of SUD during treatment (mean CS treatment length 27.9 months). Younger age and comorbid antisocial personality disorder were associated with relapse. In a logistic regression analysis, cannabis abstinence for more than 12 months was a negative predictor for relapse of SUD. CS treatment does not precipitate onset of SUD in adults without previous SUD.

Functional impairment and occupational outcome in adults with ADHD.

OBJECTIVE: ADHD is associated with poor functional outcomes. The objectives were to investigate the prevalence of functional impairment and occupational status in a clinically referred sample of adults with ADHD and explore factors predicting occupational outcome. METHOD: A sample of 149 adults with a confirmed diagnosis of ADHD participated in the present study. Cross-sectional data were collected from the participant's medical records and from self-report questionnaires. A multiple regression model was applied to identify possible predictors of occupational outcome. RESULTS: Only 22.2% had ordinary work as their source of income, compared with 72% in the general population. The most prevalent comorbid disorders were lifetime depression (37.8%), substance abuse (28.1%), and alcohol abuse (23.3%). Age at first treatment with central stimulants and inattentiveness negatively predicted occupational outcome. CONCLUSION: Adult ADHD was associated with lower educational attainment and lower level of employment. Later age of first central stimulant treatment and higher inattentiveness ratings were associated with lower level of employment.

Treatment of adult ADHD: is current knowledge useful to clinicians?

Psychostimulant drugs have for decades been considered the cornerstone of ADHD treatment. Non-stimulant drugs have also been reported successful. However, many controlled studies exclude patients with comorbidities typical for patients seen in clinical setting. Many patients are also considered non-responders to medication. Current knowledge might not be directly useful to clinicians. The present article reviews the literature on pharmacological and psychotherapeutic treatment in adult ADHD emphasizing comorbidity and other clinically important factors, as well as ADHD specific outcomes. Thirty-three relevant studies of pharmacotherapy and three studies of psychotherapy were included. Most subjects had little current comorbidity, but some studies included subjects with substance use disorder. Significant effect of treatment on ADHD symptoms was found in most studies using pharmacotherapy and all studies of psychotherapy. Both positive and negative effects on comorbid anxiety and depression measures were reported. Pharmacotherapy did not seem to have effect on substance use disorder. Few pharmacotherapy studies conducted any long-term follow-up; two studies that did, found that most subjects had discontinued medication. A clear-cut dose-respons relationship was not substanciated. In conclusion, clinicians have good support for both pharmacological and psychotherapeutic treatment of ADHD in adults, but should take additional measures to deal with comorbidities as well as treatment adherence.

ADHD in adults: a study of clinical characteristics, impairment and comorbidity.

In this study, we explored the clinical characteristics, impairment and comorbidity in a sample of 45 adult patients with attention-deficit/hyperactivity disorder (ADHD). The collection of data is based on a naturalistic, retrospective approach using medical records documenting a comprehensive assessment of the patients. The sample was severely impaired in terms of academic achievement, employment and criminality, and had very high levels of comorbidity, especially alcohol and drug abuse, antisocial personality disorder and depression. Despite a high degree of contact with child psychiatric services in childhood, very few were diagnosed with ADHD, and many had a long period of psychiatric treatment as adults before the ADHD diagnosis was made. ADHD is in this sample of adults associated with severe impairment and comorbidity, and the connection between impairment and lack of proper diagnosis and treatment is discussed.